(VIANEWS) – The Innrs Artificial Intelligence algorithm has been making predictions about the next day stock price and guessing some of them correctly.
We, at Via News, will follow this AI algorithm and publish the results every week day.
Yesterday’s AI prediction for today would produce a ROI of 0.05% if an investor was to invest following yesterday’s Innrs AI suggestion.
See the data in the table below.
| Financial Asset | Accuracy | Prediction | ROI |
|---|---|---|---|
| UBS Group (UBS) | 83.86% | $24.83 | 1.55% ✅ |
| Royalty Pharma (RPRX) | 93.66% | $30.03 | 1.3% ✅ |
| Hilton Worldwide Holdings (HLT) | 84.31% | $149.22 | 1.17% ✅ |
| DocuSign (DOCU) | 85.12% | $45.99 | 1.08% ✅ |
| GlaxoSmithKline (GSK) | 84.13% | $35.44 | 0.92% ✅ |
| HCA Holdings (HCA) | 83.73% | $283.54 | 0.91% ✅ |
| Ross Stores (ROST) | 83.55% | $123.25 | 0.82% ✅ |
| NewMarket (NEU) | 83.9% | $465.77 | 0.7% ✅ |
| General Motors (GM) | 88.68% | $33.28 | 0.49% ✅ |
| Fifth Third Bancorp (FITBI) | 84.71% | $25.59 | 0.39% ✅ |
| Ulta Beauty (ULTA) | 83.89% | $419.42 | 0.31% ✅ |
| PT Telekomunikasi (TLK) | 84.28% | $24.62 | 0.16% ✅ |
| Regeneron Pharmaceuticals (REGN) | 88.71% | $852.4 | -0.06% |
| Merck (MRK) | 88.06% | $112.95 | -1.02% |
| Aware, Inc. (AWRE) | 86.74% | $1.39 | -2.04% |
| Xerox Corporation (XRX) | 94.45% | $15.41 | -2.18% |
| ImmunoGen (IMGN) | 86.25% | $16.45 | -3.6% |
1. UBS Group (UBS)
UBS Group has been having an accuracy rate of 83.86% over the last 10 sessions. Previous close price was $24.55 the AI prediction was $24.83 and today’s closing price was $24.93. The intraday ROI for UBS Group (UBS) was 1.55%.
Shares of UBS Group rose by a staggering 10.74% in from $22.17 to $24.55 at 22:29 EST on Monday, following the last session’s upward trend. NYSE is jumping 0.71% to $15,879.59, after two consecutive sessions in a row of gains.
UBS Group AG provides financial advice and solutions to private, institutional, and corporate clients worldwide.
Earnings Per Share
As for profitability, UBS Group has a trailing twelve months EPS of $1.96.
PE Ratio
UBS Group has a trailing twelve months price to earnings ratio of 12.52. Meaning, the purchaser of the share is investing $12.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.27%.
Volatility
UBS Group’s last week, last month’s, and last quarter’s current intraday variation average was 1.19%, 0.51%, and 1.16%.
UBS Group’s highest amplitude of average volatility was 1.38% (last week), 1.13% (last month), and 1.16% (last quarter).
Moving Average
UBS Group’s worth is way higher than its 50-day moving average of $21.15 and way higher than its 200-day moving average of $20.15.
Sales Growth
UBS Group’s sales growth is negative 3.8% for the ongoing quarter and 33.9% for the next.
Revenue Growth
Year-on-year quarterly revenue growth declined by 7%, now sitting on 33.76B for the twelve trailing months.
More news about UBS Group.
2. Royalty Pharma (RPRX)
Royalty Pharma has been having an accuracy rate of 93.66% over the last 10 sessions. Previous close price was $30 the AI prediction was $30.03 and today’s closing price was $30.39. The intraday ROI for Royalty Pharma (RPRX) was 1.3%.
Shares of Royalty Pharma slid 3.9% in from $31.22 to $30.00 at 22:29 EST on Monday, after two consecutive sessions in a row of gains. NASDAQ is rising 0.84% to $13,705.13, after two sequential sessions in a row of gains.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
Earnings Per Share
As for profitability, Royalty Pharma has a trailing twelve months EPS of $0.55.
PE Ratio
Royalty Pharma has a trailing twelve months price to earnings ratio of 54.54. Meaning, the purchaser of the share is investing $54.54 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.66%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 5.6% and a drop 39.1% for the next.
Volume
Today’s last reported volume for Royalty Pharma is 2799670 which is 18.25% above its average volume of 2367500.
Sales Growth
Royalty Pharma’s sales growth is 4.9% for the present quarter and 11.5% for the next.
Yearly Top and Bottom Value
Royalty Pharma’s stock is valued at $30.00 at 22:29 EST, way under its 52-week high of $44.47 and higher than its 52-week low of $28.98.
More news about Royalty Pharma.
3. Hilton Worldwide Holdings (HLT)
Hilton Worldwide Holdings has been having an accuracy rate of 84.31% over the last 10 sessions. Previous close price was $147 the AI prediction was $149.22 and today’s closing price was $148.72. The intraday ROI for Hilton Worldwide Holdings (HLT) was 1.17%.
Shares of Hilton Worldwide Holdings dropped 5.33% in from $155.28 to $147.00 at 22:29 EST on Monday, following the last session’s upward trend. NYSE is rising 0.71% to $15,879.59, after two sequential sessions in a row of gains.
Hilton Worldwide Holdings Inc., a hospitality company, engages in managing, franchising, owning, and leasing hotels and resorts.
Earnings Per Share
As for profitability, Hilton Worldwide Holdings has a trailing twelve months EPS of $4.77.
PE Ratio
Hilton Worldwide Holdings has a trailing twelve months price to earnings ratio of 30.82. Meaning, the purchaser of the share is investing $30.82 for every dollar of annual earnings.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Hilton Worldwide Holdings’s stock is considered to be overbought (>=80).
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Aug 23, 2023, the estimated forward annual dividend rate is 0.6 and the estimated forward annual dividend yield is 0.41%.
Moving Average
Hilton Worldwide Holdings’s value is under its 50-day moving average of $148.84 and higher than its 200-day moving average of $142.20.
More news about Hilton Worldwide Holdings.
4. DocuSign (DOCU)
DocuSign has been having an accuracy rate of 85.12% over the last 10 sessions. Previous close price was $48.26 the AI prediction was $45.99 and today’s closing price was $47.74. The intraday ROI for DocuSign (DOCU) was 1.08%.
Shares of DocuSign fell by a staggering 11.62% in from $54.61 to $48.26 at 22:29 EST on Monday, following the last session’s downward trend. NASDAQ is rising 0.84% to $13,705.13, after two successive sessions in a row of gains.
DocuSign, Inc. provides electronic signature solution in the United States and internationally.
Earnings Per Share
As for profitability, DocuSign has a trailing twelve months EPS of $-0.34.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.66%.
Sales Growth
DocuSign’s sales growth for the current quarter is 8.9%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.3%, now sitting on 2.59B for the twelve trailing months.
Yearly Top and Bottom Value
DocuSign’s stock is valued at $48.26 at 22:29 EST, way below its 52-week high of $69.45 and way above its 52-week low of $39.57.
Earnings Before Interest, Taxes, Depreciation, and Amortization
DocuSign’s EBITDA is 323.67.
More news about DocuSign.
5. GlaxoSmithKline (GSK)
GlaxoSmithKline has been having an accuracy rate of 84.13% over the last 10 sessions. Previous close price was $34.79 the AI prediction was $35.44 and today’s closing price was $35.11. The intraday ROI for GlaxoSmithKline (GSK) was 0.92%.
Shares of GlaxoSmithKline slid 2.16% in from $35.56 to $34.79 at 22:29 EST on Monday, after two consecutive sessions in a row of gains. NYSE is jumping 0.71% to $15,879.59, after two consecutive sessions in a row of gains.
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Earnings Per Share
As for profitability, GlaxoSmithKline has a trailing twelve months EPS of $3.23.
PE Ratio
GlaxoSmithKline has a trailing twelve months price to earnings ratio of 10.77. Meaning, the purchaser of the share is investing $10.77 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.22%.
Yearly Top and Bottom Value
GlaxoSmithKline’s stock is valued at $34.79 at 22:29 EST, way below its 52-week high of $39.74 and way above its 52-week low of $28.47.
More news about GlaxoSmithKline.
6. HCA Holdings (HCA)
HCA Holdings has been having an accuracy rate of 83.73% over the last 10 sessions. Previous close price was $275.05 the AI prediction was $283.54 and today’s closing price was $277.54. The intraday ROI for HCA Holdings (HCA) was 0.91%.
Shares of HCA Holdings rose 1.7% in from $270.45 to $275.05 at 22:29 EST on Monday, after two consecutive sessions in a row of gains. NYSE is rising 0.71% to $15,879.59, after two consecutive sessions in a row of gains.
HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States.
Earnings Per Share
As for profitability, HCA Holdings has a trailing twelve months EPS of $20.25.
PE Ratio
HCA Holdings has a trailing twelve months price to earnings ratio of 13.58. Meaning, the purchaser of the share is investing $13.58 for every dollar of annual earnings.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HCA Holdings’s stock is considered to be overbought (>=80).
More news about HCA Holdings.
7. Ross Stores (ROST)
Ross Stores has been having an accuracy rate of 83.55% over the last 10 sessions. Previous close price was $118.96 the AI prediction was $123.25 and today’s closing price was $119.93. The intraday ROI for Ross Stores (ROST) was 0.82%.
Shares of Ross Stores jumped 4.44% in from $113.9 to $118.96 at 22:29 EST on Monday, after two sequential sessions in a row of gains. NASDAQ is rising 0.84% to $13,705.13, after two sequential sessions in a row of gains.
Ross Stores, Inc., together with its subsidiaries, operates off-price retail apparel and home fashion stores under the Ross Dress for Less and dd's DISCOUNTS brand names in the United States.
Earnings Per Share
As for profitability, Ross Stores has a trailing twelve months EPS of $4.7.
PE Ratio
Ross Stores has a trailing twelve months price to earnings ratio of 25.31. Meaning, the purchaser of the share is investing $25.31 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 37.44%.
Moving Average
Ross Stores’s worth is higher than its 50-day moving average of $112.33 and above its 200-day moving average of $110.10.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.7%, now sitting on 19.21B for the twelve trailing months.
Yearly Top and Bottom Value
Ross Stores’s stock is valued at $118.96 at 22:29 EST, under its 52-week high of $122.70 and way higher than its 52-week low of $81.21.
Volume
Today’s last reported volume for Ross Stores is 1135180 which is 53.19% below its average volume of 2425510.
More news about Ross Stores.
8. NewMarket (NEU)
NewMarket has been having an accuracy rate of 83.9% over the last 10 sessions. Previous close price was $455.77 the AI prediction was $465.77 and today’s closing price was $458.96. The intraday ROI for NewMarket (NEU) was 0.7%.
Shares of NewMarket rose 2.26% in from $445.7 to $455.77 at 22:29 EST on Monday, following the last session’s upward trend. NYSE is rising 0.71% to $15,879.59, after two successive sessions in a row of gains.
NewMarket Corporation, through its subsidiaries, primarily engages in the manufacture and sale of petroleum additives.
Earnings Per Share
As for profitability, NewMarket has a trailing twelve months EPS of $35.95.
PE Ratio
NewMarket has a trailing twelve months price to earnings ratio of 12.68. Meaning, the purchaser of the share is investing $12.68 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.49%.
More news about NewMarket.
9. General Motors (GM)
General Motors has been having an accuracy rate of 88.68% over the last 10 sessions. Previous close price was $32.96 the AI prediction was $33.28 and today’s closing price was $33.12. The intraday ROI for General Motors (GM) was 0.49%.
Shares of General Motors dropped by a staggering 15.87% in from $39.18 to $32.96 at 22:29 EST on Monday, after two successive sessions in a row of gains. NYSE is rising 0.71% to $15,879.59, after two consecutive sessions in a row of gains.
General Motors Company designs, builds, and sells trucks, crossovers, cars, and automobile parts; and provide software-enabled services and subscriptions worldwide.
Earnings Per Share
As for profitability, General Motors has a trailing twelve months EPS of $7.16.
PE Ratio
General Motors has a trailing twelve months price to earnings ratio of 4.6. Meaning, the purchaser of the share is investing $4.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.01%.
More news about General Motors.
10. Fifth Third Bancorp (FITBI)
Fifth Third Bancorp has been having an accuracy rate of 84.71% over the last 10 sessions. Previous close price was $25.55 the AI prediction was $25.59 and today’s closing price was $25.65. The intraday ROI for Fifth Third Bancorp (FITBI) was 0.39%.
Shares of Fifth Third Bancorp jumped 0.67% in from $25.38 to $25.55 at 22:29 EST on Monday, after two consecutive sessions in a row of gains. NASDAQ is jumping 0.84% to $13,705.13, after two consecutive sessions in a row of gains.
Fifth Third Bancorp operates as a diversified financial services company in the United States.
Earnings Per Share
As for profitability, Fifth Third Bancorp has a trailing twelve months EPS of $3.48.
PE Ratio
Fifth Third Bancorp has a trailing twelve months price to earnings ratio of 7.34. Meaning, the purchaser of the share is investing $7.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.86%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.3%, now sitting on 8.21B for the twelve trailing months.
Volatility
Fifth Third Bancorp’s last week, last month’s, and last quarter’s current intraday variation average was 0.08%, 0.06%, and 0.41%.
Fifth Third Bancorp’s highest amplitude of average volatility was 0.30% (last week), 0.34% (last month), and 0.41% (last quarter).
Moving Average
Fifth Third Bancorp’s worth is above its 50-day moving average of $25.26 and higher than its 200-day moving average of $24.86.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 26, 2023, the estimated forward annual dividend rate is 1.66 and the estimated forward annual dividend yield is 6.47%.
More news about Fifth Third Bancorp.
11. Ulta Beauty (ULTA)
Ulta Beauty has been having an accuracy rate of 83.89% over the last 10 sessions. Previous close price was $409.58 the AI prediction was $419.42 and today’s closing price was $410.84. The intraday ROI for Ulta Beauty (ULTA) was 0.31%.
Shares of Ulta Beauty dropped 9.2% in from $451.08 to $409.58 at 22:29 EST on Monday, following the last session’s upward trend. NASDAQ is jumping 0.84% to $13,705.13, after two consecutive sessions in a row of gains.
Ulta Beauty, Inc. operate specialty retail stores selling cosmetics, fragrance, haircare and skincare products, and related accessories and services in the United States.
Earnings Per Share
As for profitability, Ulta Beauty has a trailing twelve months EPS of $23.72.
PE Ratio
Ulta Beauty has a trailing twelve months price to earnings ratio of 17.27. Meaning, the purchaser of the share is investing $17.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 66.08%.
More news about Ulta Beauty.
12. PT Telekomunikasi (TLK)
PT Telekomunikasi has been having an accuracy rate of 84.28% over the last 10 sessions. Previous close price was $24.32 the AI prediction was $24.62 and today’s closing price was $24.36. The intraday ROI for PT Telekomunikasi (TLK) was 0.16%.
Shares of PT Telekomunikasi dropped 1.23% in from $24.62 to $24.32 at 22:29 EST on Monday, after two sequential sessions in a row of gains. NYSE is rising 0.71% to $15,879.59, after two sequential sessions in a row of gains.
Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk provides information and communications technology, and telecommunications network services worldwide.
Earnings Per Share
As for profitability, PT Telekomunikasi has a trailing twelve months EPS of $1.33.
PE Ratio
PT Telekomunikasi has a trailing twelve months price to earnings ratio of 18.28. Meaning, the purchaser of the share is investing $18.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.18%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 13, 2023, the estimated forward annual dividend rate is 1.13 and the estimated forward annual dividend yield is 4.63%.
Yearly Top and Bottom Value
PT Telekomunikasi’s stock is valued at $24.32 at 22:29 EST, way below its 52-week high of $30.76 and higher than its 52-week low of $23.03.
More news about PT Telekomunikasi.
13. Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals has been having an accuracy rate of 88.71% over the last 10 sessions. Previous close price was $831.36 the AI prediction was $852.4 and today’s closing price was $830.89. The intraday ROI for Regeneron Pharmaceuticals (REGN) was -0.06%.
Shares of Regeneron Pharmaceuticals rose by a staggering 12.57% in from $738.53 to $831.36 at 22:29 EST on Monday, following the last session’s upward trend. NASDAQ is jumping 0.84% to $13,705.13, after two consecutive sessions in a row of gains.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Earnings Per Share
As for profitability, Regeneron Pharmaceuticals has a trailing twelve months EPS of $37.84.
PE Ratio
Regeneron Pharmaceuticals has a trailing twelve months price to earnings ratio of 21.97. Meaning, the purchaser of the share is investing $21.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.23%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Regeneron Pharmaceuticals’s stock is considered to be overbought (>=80).
Yearly Top and Bottom Value
Regeneron Pharmaceuticals’s stock is valued at $831.36 at 22:29 EST, under its 52-week high of $847.50 and way above its 52-week low of $572.22.
More news about Regeneron Pharmaceuticals.
14. Merck (MRK)
Merck has been having an accuracy rate of 88.06% over the last 10 sessions. Previous close price was $110.05 the AI prediction was $112.95 and today’s closing price was $108.93. The intraday ROI for Merck (MRK) was -1.02%.
Shares of Merck jumped 3.67% in from $106.15 to $110.05 at 22:29 EST on Monday, following the last session’s downward trend. NYSE is rising 0.71% to $15,879.59, after two consecutive sessions in a row of gains.
Merck & Co., Inc. operates as a healthcare company worldwide.
Earnings Per Share
As for profitability, Merck has a trailing twelve months EPS of $1.21.
PE Ratio
Merck has a trailing twelve months price to earnings ratio of 90.95. Meaning, the purchaser of the share is investing $90.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.61%.
More news about Merck.
15. Aware, Inc. (AWRE)
Aware, Inc. has been having an accuracy rate of 86.74% over the last 10 sessions. Previous close price was $1.47 the AI prediction was $1.39 and today’s closing price was $1.5. The intraday ROI for Aware, Inc. (AWRE) was -2.04%.
Shares of Aware, Inc. dropped by a staggering 15.65% in from $1.74 to $1.47 at 22:29 EST on Monday, following the last session’s upward trend. NASDAQ is jumping 0.84% to $13,705.13, after two successive sessions in a row of gains.
Aware, Inc., a authentication company, provides biometrics software products and solutions for government agencies and commercial entities in the United States, Brazil, the United Kingdom, and internationally.
Earnings Per Share
As for profitability, Aware, Inc. has a trailing twelve months EPS of $-0.16.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.86%.
More news about Aware, Inc..
16. Xerox Corporation (XRX)
Xerox Corporation has been having an accuracy rate of 94.45% over the last 10 sessions. Previous close price was $15.57 the AI prediction was $15.41 and today’s closing price was $15.91. The intraday ROI for Xerox Corporation (XRX) was -2.18%.
Shares of Xerox Corporation slid 4.05% in from $16.23 to $15.57 at 22:29 EST on Monday, after three sequential sessions in a row of gains. NYSE is jumping 0.71% to $15,879.59, after two sequential sessions in a row of gains.
Xerox Holdings Corporation, a workplace technology company, designs, develops, and sells document management systems and solutions in the Americas, Europe, the Middle East, Africa, India, and internationally.
Earnings Per Share
As for profitability, Xerox Corporation has a trailing twelve months EPS of $-1.7.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.79%.
More news about Xerox Corporation.
17. ImmunoGen (IMGN)
ImmunoGen has been having an accuracy rate of 86.25% over the last 10 sessions. Previous close price was $16.12 the AI prediction was $16.45 and today’s closing price was $15.54. The intraday ROI for ImmunoGen (IMGN) was -3.6%.
Shares of ImmunoGen slid 9.55% in from $17.82 to $16.12 at 22:29 EST on Monday, following the last session’s downward trend. NASDAQ is jumping 0.84% to $13,705.13, after two sequential sessions in a row of gains.
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients.
Earnings Per Share
As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.69.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -49.15%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 109.7% and 126.1%, respectively.
Previous days news about ImmunoGen
- : immunogen stock jumps after licensing deal with Japan’s takeda pharmaceutical. According to MarketWatch on Monday, 28 August, "Shares of ImmunoGen Inc. jumped 1.7% in premarket trading Monday, after the Massachusetts-based drug maker announced a collaboration with Takeda Pharmaceutical Co. Ltd. "
More news about ImmunoGen.
